Erasca (ERAS) Long-Term Investments (2021 - 2026)
Erasca posted quarterly Long-Term Investments of $164.7 million for Q1 2026, up 54.68% year-on-year from $106.5 million in Q1 2025, and up 150.63% on a QoQ basis from $65.7 million in Q4 2025.
Erasca (ERAS) has 6 years of Long-Term Investments data on file, last reported at $164.7 million in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Investments rose 54.68% year-over-year to $164.7 million; the trailing twelve-month figure through Mar 2026 stood at $164.7 million (up 54.68% YoY), and the FY2025 full-year result was $65.7 million, down 53.77% from the prior year.
- Long-Term Investments for Q1 2026 stood at $164.7 million, up from $65.7 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $164.7 million in Q1 2026 and bottomed at $9.6 million in Q3 2022.
- The 5-year median for Long-Term Investments is $58.8 million (2024), against an average of $71.3 million.
- The widest annual swing landed in 2024, when Long-Term Investments soared 1374.42%; it then plunged 53.77% in 2025.
- A 5-year view of Long-Term Investments shows it stood at $9.6 million in 2022, then increased by 0.44% to $9.6 million in 2023, then jumped by 1374.42% to $142.2 million in 2024, then slumped by 53.77% to $65.7 million in 2025, then jumped by 150.63% to $164.7 million in 2026.
- The last three Long-Term Investments figures came in at $164.7 million (Q1 2026), $65.7 million (Q4 2025), and $74.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 164.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 164.72 Mn |
| Dec 31, 2025 | 65.72 Mn |
| Sep 30, 2025 | 73.98 Mn |
| Jun 30, 2025 | 86.09 Mn |
| Mar 31, 2025 | 106.49 Mn |
| Dec 31, 2024 | 142.16 Mn |
| Sep 30, 2024 | 144.40 Mn |
| Jun 30, 2024 | 51.80 Mn |
| Dec 31, 2023 | 9.64 Mn |
| Sep 30, 2023 | 46.90 Mn |
| Jun 30, 2023 | 48.08 Mn |
| Sep 30, 2022 | 9.60 Mn |
| Jun 30, 2022 | 19.30 Mn |
| Mar 31, 2022 | 29.22 Mn |
| Dec 31, 2021 | 44.77 Mn |
| Jun 30, 2021 | 5.00 Mn |